Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

us risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our ability to successfully complete and bring on line additional manufacturing lines; our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program and the level of sales through that program; other unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... N.J. , March 5, 2015 CANTEL MEDICAL ... for its second quarter ended January 31, 2015 on Thursday, ... call to discuss the results at 11:00 AM ET. ... 407-8033 approximately 5 to 10 minutes before the beginning of ... replay of the call will be available from Thursday, March ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... WALTHAM, Mass., Jan. 4, 2011 Syndax Pharmaceuticals, Inc., ... Horobin, M.D., the company,s president and CEO, will present ... 2011 at 10:00 a.m. PT at the Parc 55 ... include the recently reported results from a randomized phase ...
... Jan. 4, 2011 STAAR Surgical Company (Nasdaq: ... and marketer of minimally invasive ophthalmic products, today ... ICL implants in patients has exceeded 200,000.  Since ... used in refractive eye surgery as an alternative ...
Cached Medicine Technology:STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 2STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 3
(Date:3/6/2015)... March 06, 2015 Dr. Amy Reed, who ... a ban on the use of power morcellators ( http://www.morcellatorlawsuit2015.com ... the cancer that prompted the launch of their public health ... week that the 41-year-old mother of six had recently undergone ... in her spine. Dr. Reed had been in remission for ...
(Date:3/6/2015)... March 06, 2015 Sanjay Gupta, ... deliver a keynote address at ATA 2015, the ... and Trade Show and world’s largest telemedicine, telehealth ... neurosurgeon, delivers medical correspondence for several of CNN’s ... and documentaries including his DuPont Award winning WEED ...
(Date:3/6/2015)... Ticket Down is a reliable source for authentic ... Clara, California. This state-of-the-art stadium opened on July 17, ... events. , The “Kick the Dust Up Tour” featuring country ... the west coast and Levi’s Stadium. The show at the ... August 29 and fans of the award-winning artist will be ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 ... the leader in the natural products coffee drinks category, ... 100 Cleanest Packaged Foods Awards for its Double ... puts packaged foods to the test to find the ... they must “taste absolutely delicious.” , “As a company ...
(Date:3/6/2015)... San Jose, California (PRWEB) March 06, 2015 ... cancer is one of the most common forms of ... women worldwide. Breast cancer can be screened through various ... among others. Mammography however remains the gold standard technique ... factors such as cost, time taken for the procedure, ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 2Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 3Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 4Health News:CNN’s Dr. Sanjay Gupta Among Headliners at American Telemedicine Association 2015 Annual Meeting 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 2Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 3Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3
... removed from product -, WAYNE, N.J., May 19 ... of the liquid Leukine(R),(sargramostim) 500 mcg vial has been ... and is now available for patients and physicians,in the ... disodium),which was in the product,s liquid 500 mcg vial ...
... census, Americans office workers spend an average of 52 ... Many recent studies on job satisfaction have shown that ... under artificial light in windowless offices, report reduced job ... make office environments more conducive to productivity and employee ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
... VIEW, Calif., May 19 Alexza,Pharmaceuticals, Inc. ... Jeffrey S.,Williams has rejoined the company in ... Ltd., a wholly owned subsidiary of Alexza. ... the Alexza,subsidiary in Singapore and establishing potential ...
... LLC, the world,s,first mobile voice-activation solution for e-Health ... J. Zecchini as its Chief,Operating Officer and Chief ... be responsible for all operations and technology functions., ... to our MediVoice team," said,Anthony V. Milone, Board ...
... CLARA, Calif., May 19 FLARE Santa,Clara HIV ... (AACI), The Billy DeFrank Center Lesbian and Gay ... Health Department, Asian,& Pacific Islander Wellness Center present ... Thursday, May 22, 2008 from 11 to 2 ...
Cached Medicine News:Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 2Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 3Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 4Health News:Greener offices make happier employees 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3Health News:MediVoice Announces Appointment of Edward J. Zecchini as Chief Operating Officer & Chief Technology Officer 2
... SDS Recall marketing software enables the efficient ... The module also has many built-in time ... auto capitalization of name fields and numerous ... and accurate data input. The pre-defined options ...
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
Medicine Products: